Welcome to Roche-HIV.com

Latest News

Fifth International Congress on Drug Therapy in HIV Infection
Glasgow 22 - 26 October 2000

Satellite symposium webcast - The Road Ahead
1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina 7 - 11 July 2001
Satellite Symposium Webcast
CHANGING VIRUS - ADAPTING THERAPY A SMART living meeting Budapest, Hungary , 25 - 26 TH May, 2001
Satellite Symposium Webcast
SMART Living - Strategic Moves in AntiRetroviral Therapy
Click here for satellite symposium abstract booklet
23 October 2000
Call to Action - Roche advocates development of HIV drug potency guidelines to help physicians make optimal treatment decisions
23 October 2000
Roche HIV Protease Inhibitor Saquinavir Shows Greater In Vitro Potency Than New Drug Lopinavir

Optimising Protease Inhibitor Therapy in 2000 and Beyond

Click here to view webcast

XIII International AIDS Conference
Durban 9 - 14 July 2000

Satellite Symposia Webcast

Click here for the satellite symposium abstract booklet

10 July 2000
Important progress in treatment of HIV infection to be reported
le 10 juillet 2000
Roche annonce d. importants progrès dans le traitement de l. infection à VIH

10. Juli 2000
Wichtiger Fortschritt Bei Der Behandlung Der HIV-Infektion

10 de julio del 2000
Nueva información sobre importantes avancesen el tratamiento de la infección por el VIH

Click here for more information on fusion inhibition (includes video clips, a feature interview and visuals)

4th International Workshop on HIV Drug Resistance and Treatment Strategies
Siteges 2000

15 June 2000
Blood levels of Fortovase increase with a mini-dose of Ritonavir

6th Annual BHIVA Meeting
Edinburgh 24 - 26 March 2000

26 March 2000
Interactive presentations and news from the Roche Symposium, including the latest information on genotyping, phenotyping and therapeutic drug monitoring in long-term HIV/AIDS treatment

7th Conference on Retroviruses and Opportunistic Infections
San Francisco 30 January - 2 February 2000

3 February 2000
Investigational aids-related oral drug valganciclovir provides comparable results to intravenous cymevene

2 February 2000
Viracept combination in pregnant women prevents HIV infection in newborns, early study shows

le 2 Fevrier 2000
Selon une etude, le traitement au viracept en association administre aux femmes enceintes empeche l'infection a VIH chez les nourrissons

2 Februar 2000
Kombination mit viracept bei schwangeren schützt vor HIV-infektion der neugeborenen, so eine frühe studie / weitere studie beleuchtet viracept als teil der behandlung von kindern

2 Febrero 2000
Un estudio clinico comprueba que viracept es eficaz para impedir la transmision del vih de la madre al bebe
2 February 2000
Shifting treatment demographics highlighted need to manage long-term HIV treatment options
le 2 Fevrier 2000
L'evolution demographique des traitements HIV fait ressortir le besoin de gerer les differentes options

2 Februar 2000
Sich verschiebende behandlungsdemographien stellen notwendigkeit in den vordergrund, langfristige HIV-behandlungsmöglichkeiten zu schaffen

2 Febrero 2000
Las líneas generales ias potencian el uso de terapias anti-VIH a largo plazo personalizadas

1 February 2000
Roche and Trimeris report clinical progress in development of HIV fusion inhibitors
le 1 Fevrier 2000
Les Societes Roche et Trimeris presentent des progres cliniques dans le developpement d'inhibiteurs de fusion VIH

1 Februar 2000
Roche und Trimeris berichten über klinischen fortschritt in der entwicklung von HIV fusions-inhibitoren

1 Febrero 2000
Roche y Trimeris informan de progresos clínicos en el desarrollo de inhibidores de fusión del VIH

Euro - AIDS '99
Lisbon 23-27 October 1999

26 October 1999
Viracept twice-daily dosing shows long-term anti-HIV effectiveness, study shows

26 October 1999
New studies show real-life advantages of Viracept in efficacy, tolerability, drug resistance and convenience

25 October 1999
New Fusion Inhibitor T-20 combination regimen reduces HIV levels in heavily pre-treated patients

le 25 octobre
Un nouveau traitement d'Association par l'Inhibiteur de Fusion T-20 diminue la concentration du VIH chez les patients qui ont reçu un traitement intensif

25. October 1999
Die Neue kombinationstherapie mit dem fusionshemmer T-20 senkt die HIV-belastung bei umfangreich vorbehandelten patienten

25 de octubre de 1999
T-20, un nuevo regimen de combinación de inhibidor de fusión reduce los niveles de VIH en pacientes con tratamientos anteriores muy estrictos

25 October 1999
Fortovase once-a-day dosing shows promise in first study in HIV-positive individuals
25 October 1999
Treatment including Fortovase shows significant promise to eliminate HIV transmission from mother to infant
25 October 1999
Study highlights potential for more convenient once-a-day administration

24 October 1999
'Biting the Chameleon' Symposium: Strategies to outwit a changing virus

39th Interscience Conference on Antimicrobial Agents and Chemotherapy
San Francisco 26-29 September 1999

27 September 1999
New Aids Study Suggests T-20-Containing Regimens Reduces HIV in Heavily Pre-Treated Patients

San Francisco, le 27 septembre
Une nouvelle étude sur le sida laisse entendre que les régimes thérapeutiques intégrant le t-20 réduisent l. activité du vih chez les patients recevant un traitement intensif de longue date

San Francisco, 27. September 1999
Neue AIDS-Studie suggeriert, dass T-20 enthaltende Dosierungen die Virale HIV-Aktivität bei umfangreich vorbehandelten Patienten reduziert

San Francisco, 27 de septiembre de 1999
Un nuevo estudio sugiere que el tratamiento con el medicamento t-20 reduce la presencia del vih en la sangre

Sixteen-Week Analysis of Heavily Pre-Treated Patients Receiving T-20 As A Component of Multi-Drug Salvage Therapy (T20-205)

T-20 Fact Sheet

http://www.Trimeris.com/

See Fusion Inhibition in the HIV Lifecycle

San Francisco 27 September 1999
Data Presented at ICAAC Support First-line Use of Viracept

San Francisco, le 27 septembre
Les données présentées dans le cadre du congrés de l. ICAAC appuient l. utilisation de viracept comme traitement de premiére intention

San Francisco, 27. September 1999
Die bei der ICAAC vorgelegten Daten bekräftigen bevorzugte Anwendung von VIRACEPT

San Francisco, 27 de septiembre de 1999
Los datos presentados en el ICAAC apoyan la utilización de viracept como terapia de primera línea

Backgrounder
Cross Resistance Data Presented at ICAAC Support First-line Use of Viracept

26 September 1999
Strong Promise for Once-A-Day Dosing of Fortovase®, Study Shows

San Francisco, le 26 septembre
Une étude révèle l. activité prometteuse de fortovase à dose quotidienne unique

San Francisco, 26. September 1999
Studie zeigt, dass die einmal tägliche Dosierung mit Fortovase

San Francisco, 26 de septiembre de 1999
Un estudio muestra el potencial del nuevo regimen de una dosis diaria de fortovase

Backgrounder
Study Highlights Potential for More Convenient Once-A-Day Administration

Fusion Inhibition News

Basel, 12 July 1999
Roche and Trimeris sign Agreement to Develop Trimeris's compounds

^®
Releasing the Power of Saquinavir

European Union Launch

Press Materials
Data Compendium
Fortovase Launch Symposium - Releasing the Power of Saquinavir
Geneva, 7-9 May 1999
Genotyping Launch Symposium - Responding to Resistance
Geneva, 7-9 May 1999
GREAT Trial - Genotypic Resistance Evaluation to Aid Therapy-switching

The Congress Centre Archive is a fully searcheable collection of information & materials from past events. The collection of materials - including highlights, abstracts, posters - is continually updated with materials from various events as they happen.

Click here to search the Congress Centre Archive.

top